福路博克，一种重组血凝素流感疫苗。
FluBlok, a recombinant hemagglutinin influenza vaccine.
作者信息
Cox Manon M J, Patriarca Peter A, Treanor John
机构信息
Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA.
出版信息
Influenza Other Respir Viruses. 2008 Nov;2(6):211-9. doi: 10.1111/j.1750-2659.2008.00053.x.
Abstract
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
摘要
FluBlok是一种利用杆状病毒表达系统在昆虫细胞培养中生产的重组三价血凝素（HA）疫苗，为目前基于鸡蛋的三价灭活流感疫苗（TIV）生产工艺提供了一种有吸引力的替代方案。FluBlok含有的HA是TIV的三倍，且不含鸡蛋蛋白或防腐剂。本综述讨论了用于支持FluBlok在美国“加速批准”机制下获得许可的四项主要临床研究。
相似文献
1
FluBlok, a recombinant hemagglutinin influenza vaccine.
Influenza Other Respir Viruses. 2008 Nov;2(6):211-9. doi: 10.1111/j.1750-2659.2008.00053.x.
2
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27.
3
FluBlok, a next generation influenza vaccine manufactured in insect cells.
Biologicals. 2009 Jun;37(3):182-9. doi: 10.1016/j.biologicals.2009.02.014. Epub 2009 Mar 17.
4
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28.
5
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9.
6
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.
J Infect Dis. 1996 Oct;174(4):838-41. doi: 10.1093/infdis/174.4.838.
7
Production of a novel influenza vaccine using insect cells: protection against drifted strains.
Influenza Other Respir Viruses. 2007 Jan;1(1):35-40. doi: 10.1111/j.1750-2659.2006.00007.x.
8
Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
Vaccine. 2009 Dec 11;28(2):379-85. doi: 10.1016/j.vaccine.2009.10.037. Epub 2009 Oct 29.
9
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
J Infect Dis. 2006 May 1;193(9):1223-8. doi: 10.1086/503050. Epub 2006 Mar 28.
10
Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.
Drugs. 2013 Aug;73(12):1357-66. doi: 10.1007/s40265-013-0103-6.
引用本文的文献
1
Advancements in the application and research of baculovirus vector vaccines for respiratory diseases in human.
Front Microbiol. 2025 Mar 13;16:1558482. doi: 10.3389/fmicb.2025.1558482. eCollection 2025.
2
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.
Virus Res. 2025 May;355:199563. doi: 10.1016/j.virusres.2025.199563. Epub 2025 Mar 24.
3
Characterization of Endogenous Retroviral-like Particles Expressed from the Sf9 Cell Line.
Viruses. 2025 Jan 21;17(2):136. doi: 10.3390/v17020136.
4
Protein Expression Platforms and the Challenges of Viral Antigen Production.
Vaccines (Basel). 2024 Nov 28;12(12):1344. doi: 10.3390/vaccines12121344.
5
Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance.
Sci Rep. 2024 Nov 8;14(1):27190. doi: 10.1038/s41598-024-72716-1.
6
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.
bioRxiv. 2024 Sep 12:2024.09.12.612748. doi: 10.1101/2024.09.12.612748.
7
A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses.
Vaccines (Basel). 2024 Sep 2;12(9):1008. doi: 10.3390/vaccines12091008.
8
Modifying Naturally Occurring, Nonmammalian-Sourced Biopolymers for Biomedical Applications.
ACS Biomater Sci Eng. 2024 Oct 14;10(10):5915-5938. doi: 10.1021/acsbiomaterials.4c00689. Epub 2024 Sep 11.
9
Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants.
Vaccines (Basel). 2024 Jul 12;12(7):764. doi: 10.3390/vaccines12070764.
10
Preliminary Findings From the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: A Randomized Controlled Trial.
Clin Infect Dis. 2024 Oct 15;79(4):901-909. doi: 10.1093/cid/ciae380.
本文引用的文献
1
Production of a novel influenza vaccine using insect cells: protection against drifted strains.
Influenza Other Respir Viruses. 2007 Jan;1(1):35-40. doi: 10.1111/j.1750-2659.2006.00007.x.
2
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916.
3
FluBlok, a recombinant influenza vaccine.
Curr Opin Mol Ther. 2008 Feb;10(1):75-85.
4
Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
JAMA. 2007 Apr 11;297(14):1577-82. doi: 10.1001/jama.297.14.1577.
5
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
J Infect Dis. 2006 Nov 15;194(10):1394-7. doi: 10.1086/508493. Epub 2006 Oct 6.
6
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
J Infect Dis. 2006 May 1;193(9):1223-8. doi: 10.1086/503050. Epub 2006 Mar 28.
7
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
N Engl J Med. 2006 Mar 30;354(13):1343-51. doi: 10.1056/NEJMoa055778.
8
Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.
Vaccine. 2006 Mar 15;24(12):2176-85. doi: 10.1016/j.vaccine.2005.11.005. Epub 2005 Nov 10.
9
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2002 Apr 12;51(RR-3):1-31.
10
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.
Vaccine. 2001 Feb 8;19(13-14):1732-7. doi: 10.1016/s0264-410x(00)00395-9.
Zotero 插件